Variant Pharmaceuticals
2200 N. Commerce Parkway
Suite 200
Weston
Florida
33326
United States
Tel: 954-529-2109
Website: http://www.variantpharma.com/
About Variant Pharmaceuticals
Variant is an emerging specialty pharmaceutical company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases.Our accomplished leadership team, each with more than 15 years of demonstrated success in the biopharmaceutical and medical industries, focuses on assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors.
YEAR FOUNDED:
2014
LEADERSHIP:
Co-Founder and CEO: Stephen C. Glover
Acting CSO: Nicholas Labella, Jr. MS, RPh
Acting CMO: Pablo A. Guzman, MD, FACC
Acting VP, Development and Marketing: Karen Cashmere
Acting VP, Finance: Peter Wolfe
Acting VP, Corporate Development: Melda Uzbil
PIPELINE:
Please click here for Variant Pharma's pipeline.
7 articles about Variant Pharmaceuticals
-
Varian Announces First Quarter Fiscal Year 2020 Earnings Release Date
12/18/2019
Varian (NYSE: VAR) today announced its first quarter fiscal year 2020 earnings release date.
-
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
12/3/2018
Funds will accelerate clinical development of VAR 200, 2-hydroxypropyl-beta-cyclodexrtrin (2HPβCD), for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disease
-
Variant Pharmaceuticals Submits Application for U.S. Orphan Drug Designation for VAR 200 (2-Hydroxypropyl-β-Cyclodextrin) To Treat Focal Segmental Glomerulosclerosis (FSGS)
10/30/2018
IND to be submitted early 2019, with phase 2a clinical trial initiation following IND acceptance
-
Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-β-Cyclodextrin (2HPβCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS)
10/24/2018
Variant Pharmaceuticals (Variant), a clinical stage orphan drug company developing first-in-class drugs for patients with rare diseases, announced today publication of preclinical data evaluating 2HPβCD in experimental models of Alport Syndrome and FSGS.
-
Variant Pharmaceuticals Receives Notice of Allowance in Two U.S. Patent Applications Covering Lead Compound, 2-hydroxypropyl-β-cyclodextrin, a Phase 2a-ready Asset for Rare Renal Disease, Focal Segmental Glomerulosclerosis (FSGS)
10/16/2018
Patents will provide protection until at least 2031 and 2033 for U.S. patent applications 14/967,831 and 14/391,236 respectively
-
Variant Pharmaceuticals Enhances Its Board of Directors with Three New Members
10/9/2018
Robert (Rob) G. Finizio: Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc
-
World Renowned Experts Join Variant Pharma Scientific Advisory Board
11/30/2016